The business of Big Pharma

Major scientific advances are producing novel treatments for everything from cancer to hemophilia, and Reuters is providing unparalleled coverage of the resulting upheaval to global healthcare. New breakthroughs have emboldened Big Pharma to demand previously unimaginable prices and to recruit patient advocates to plead their case to regulators and insurers like never before. From the United States and Canada to Europe and Japan, governments are struggling to keep up with budget-busting medicines, and seek new strategies to contain those costs. Reuters is delivering exclusive news and insight on this new era of medicine and what it means for patients, businesses and investors.